Translating Research Into Practice
The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial
G. Lita Smith, MS, RN, ACNP
From University of Michigan, Ann Arbor, Michigan
Author's disclosures of potential conflicts of interest are found at the end of this article.
Correspondence to: G. Lita Smith, MS, RN, ACNP, University of Michigan, Breast Oncology, 1500 East Medical Center Drive, Ann Arbor, MI 48109. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2014;5:57-60# |
DOI: 10.6004/jadpro.2014.5.1.5 |
© 2014 Harborside Press®
Review of “Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial” by Davies et al. (2013), Lancet, 381, 805–816. For another perspective on the ATLAS trial, please see the article on randomization and adjusting for covariates by Dustin Dickerson starting on page 61.
For access to the full length article, please sign in